PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers - Institut Curie Accéder directement au contenu
Article Dans Une Revue Journal of Clinical Medicine Année : 2022

PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers

Diego Teyssonneau
  • Fonction : Auteur correspondant
Guillaume Ploussard

Résumé

Despite recent improvements in survival, metastatic castration-resistant prostate cancers (mCRPCs) remain lethal. Alterations in genes involved in the homologous recombination repair (HRR) pathway are associated with poor prognosis. Poly-ADP-ribose polymerase (PARP) inhibitors (PARPis) have demonstrated anti-tumoral effects by synthetic lethality in patients with mCRPCs harboring HRR gene alterations, in particular BRCA2. While both olaparib and rucaparib have obtained government approvals for use, the selection of eligible patients as well as the prescription of these treatments within the clinical urology community are challenging. This review proposes a brief review of the rationale and outcomes of PARPi treatment, then a pragmatic vision of PARPi use in terms of prescription and the selection of patients based on molecular screening, which can involve potential genetic counseling in the case of associated germinal alterations.
Fichier principal
Vignette du fichier
jcm-11-01734.pdf (817.08 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03664794 , version 1 (23-01-2023)

Identifiants

Citer

Diego Teyssonneau, Antoine Thiery-Vuillemin, Charles Dariane, Eric Barret, Jean-Baptiste Beauval, et al.. PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers. Journal of Clinical Medicine, 2022, 11 (6), ⟨10.3390/jcm11061734⟩. ⟨hal-03664794⟩
48 Consultations
64 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More